MediciNova Inc. (MNOV) announced after the close Tuesday the presentation of preliminary results from a Phase 1b study of MN-166 in methamphetamine addiction at the 75th Annual Meeting of the College on Problems of Drug Dependence in San Diego.
MediciNova spiked to the upside at the open Wednesday and is now higher by 0.93 at $3.50 on above average volume. The stock has surged to a 1-month high.
For comments and feedback: editorial@rttnews.com